Евразийские клинические рекомендации по диагностике, профилактике и лечению сердечно-сосудистых осложнений при противоопухолевой терапии (2022)

Автор: Чазова И. Е., Агеев Ф. Т., Аксенова А. В., Виценя М. В., Гиляров М. Ю., Мартынюк Т. В., Панченко Е. П., Полтавская М. Г., Потиевская В. И., Трофимова О. П., Федоткина Ю. А.

Журнал: Евразийский кардиологический журнал @eurasian-cardiology-journal

Рубрика: Клинические рекомендации

Статья в выпуске: 1, 2022 года.

Бесплатный доступ

Отказ от ответственности. Рекомендации ЕАК отражают точку зрения ЕАК и были подготовлены после тщательного изучения научных и медицинских данных, имеющихся на момент их публикации. ЕАК не несут ответственности в случае какого-либо противоречия, несоответствия и / или неоднозначности между Рекомендациями ЕАК и любыми другими официальными рекомендациями или руководствами, выпущенными соответствующими органами общественного здравоохранения, в частности, в отношении правильного использования медицинских или терапевтических стратегий. Медицинским работникам рекомендуется в полной мере учитывать Рекомендации ЕАК при оценке своего клинического суждения, а также при определении и реализации профилактических, диагностических или терапевтических медицинских стратегий. Тем не менее, Рекомендации ЕАК никоим образом не отменяют индивидуальную ответственность медицинских работников за принятие надлежащих и точных решений с учетом состояния здоровья каждого пациента и в консультации с этим пациентом и, при необходимости и / или необходимости, опекуна пациента. Рекомендации ЕАК не освобождают медицинских работников от полного и тщательного рассмотрения соответствующих официальных обновленных рекомендаций или руководств, выпущенных компетентными органами общественного здравоохранения, для рассмотрения каждого медицинского случая в свете современных научно обоснованных рекомендаций в соответствии с их этическими и профессиональными обязательствами. Кроме того, медицинский работник обязан проверять действующие правила и положения, касающиеся лекарств и медицинских изделий, на момент назначения по рецепту.

Еще

Артериальная гипертония, дисфункция левого желудочка, евразийская ассоциация кардиологов, ишемическая болезнь сердца, кардиотоксичность, клинические рекомендации, легочная артериальная гипертензия, лучевая терапия, нарушение ритма и проводимости сердца, периоперационное ведение, противоопухолевая терапия, сердечная недостаточность, терапия ингибиторами контрольных точек иммунного ответа, терапия рака, тромбозы, химиотерапия

Еще

Короткий адрес: https://sciup.org/143178585

IDR: 143178585

Список литературы Евразийские клинические рекомендации по диагностике, профилактике и лечению сердечно-сосудистых осложнений при противоопухолевой терапии (2022)

  • Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments. Nat Rev Cardiol. 2015;12(11):620. https://doi.org/10.1038/nrcardio.2015.133
  • Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) [published correction appears in Eur Heart J. 2016 Dec 24;:]. Eur Heart J. 2016;37(36):2768-2801. https://doi.org/10.1093/eurheartj/ ehw211
  • Chen MH, Colan SD, Diller L. Cardiovascular disease: cause of morbidity and mortality in adult survivors of childhood cancers [published correction appears in Circ Res. 2011 Apr 15;108(8):e11]. Circ Res. 2011;108(5):619-628. https:// doi.org/10.1161/CIRCRESAHA.110.224519
  • Sawyer D, Lenihan D. Managing heart failure in cancer patients. In: Mann D., Felker G. Heart Failure: A Companion to Braunwald's Heart Disease, 3rd ed. Philadelphia, Elsevier, 2016;p. 689-96.
  • Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing highdose chemotherapy. Circulation. 2004;109(22):2749-2754. https://doi. org/10.1161/01.CIR.0000130926.51766.CC
  • Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91(5):710-717. https://doi. org/10.7326/0003-4819-91-5-710
  • Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981-1988. https://doi.org/10.n61/ CIRCULATIONAHA.114.013111
  • Ryberg M, Nielsen D, Skovsgaard T, Hansen J, Jensen BV, Dombernowsky P. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol. 1998;16(11):3502-3508. https://doi.org/10.1200/ JCO.1998.16.11.3502
  • Nielsen D, Jensen JB, Dombernowsky P, et al. Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer. J Clin Oncol. 1990;8(11):1806-1810. https://doi.org/10.1200/JC0.1990.8.11.1806
  • Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342(15):1011-1084. https://doi.org/10.1056/NEJM200004133421502
  • KuramochiY, Cote GM, Guo X, et al. Cardiac endothelial cells regulate reactive oxygen species-induced cardiomyocyte apoptosis through neuregulin-1beta/erbB4 signaling. J Biol Chem. 2004;219(49):51141-51141. https://doi. org/10.1014jbc.M408662200
  • Hedhli N, Huang Q, Kalinowski A, et al. Endothelium-derived neuregulin protects the heart against ischemic injury. Circulation. 2011;123(20):2254-2262. https://doi.org/10.1161/CIRCULATI0NAHA.110.991125
  • Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 1991;16(1):1641-1655. https://doi.org/10.1093/ emboj/16.1.1641
  • Procter M, Suter TM, de Azambuja E, et al. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol. 2010;28(21):3422-3428. https://doi.org/10.1200/ JCO.2009.26.0463
  • Ewer MS, Vooletich MT, Durand JB et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005 Nov 1;23(31):1820-6. https://doi.org/10.1200/ JCO.2005.13.300 PMID: 16258084.
  • Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):111-190. https://doi.org/10.1016j. annonc.2019.10.023
  • Lenihan D, Suter T, Brammer M, Neate C, Ross G, Baselga J. Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab [published correction appears in Ann Oncol. 2019 Jun 1;30(6):1021]. Ann Oncol. 2012;23(3):191-800. https://doi.org/10.1093/annonc/mdr294.
  • Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 2008;83(6):619-686. https://doi.org/10.4065/83.6.619
  • Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al. ICRF-181 permits longer treatment with doxorubicin in women with breast cancer [published correction appears in J Clin Oncol 1992 May;10(5):861]. J Clin Oncol. 1992;10(1):111-121. https://doi.org/10.1200/Jœ.1992.10.1.111
  • Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;91(11):2869-2819. https://doi.org/10.1002/cncr.11401
  • van Nimwegen FA, Schaapveld M, Janus CP, et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med. 2015;115(6):1001-1011. https://doi.org/10.1001/jamainternmed.2015.1180
  • Armenian SH, Sun CL, Shannon T, et al. Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation. Blood. 2011;118(23):6023-6029. https://doi.org/10.1182/blood-2011-06-358226
  • Baldini E, Prochilo T, Salvadori B, et al. Multicenter randomized phase III trial of epirubicin plus paclitaxel vs epirubicin followed by paclitaxel in metastatic breast cancer patients: focus on cardiac safety. Br J Cancer. 2004;91(1):45-49. https://doi.org/10.1038/sj.bjc.6601883
  • Fumoleau P, Roché H, KerbratP, et al. Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. Ann Oncol. 2006;11(1):85-92. https://doi.org/10.1093/annonc/ mdj034
  • Ryberg M, Nielsen D, Cortese G, Nielsen G, Skovsgaard T, Andersen PK. New insight into epirubicin cardiac toxicity: competing risks analysis of 1091 breast cancer patients. J Natl Cancer Inst. 2008;100(15):1058-1061. https:// doi.org/10.1093/jnci/djn206
  • van der Pal HJ, van Dalen EC, van Delden E, et al. High risk of symptomatic cardiac events in childhood cancer survivors. J Clin Oncol. 2012;30(13):1429-1431. https://doi.org/10.1200/JCO.2010.33.4130
  • Di Cosimo S. Heart to heart with trastuzumab: a review on cardiac toxicity. Target Oncol. 2011;6(4):189-195. https://doi.org/10.1001/s11523-011-0203-8
  • Zeglinski M, Ludke A, Jassal D et al. Trastuzumab-induced cardiac dysfunction: A «dual-hit». Exp Clin Cardiol 2011;16:10-4.
  • Клинические рекомендации. Рак молочной железы. Рубрикатор КР (minzdrav.gov.ru).
  • Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Herceptin Adjuvant Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659-12.
  • Bowles EJ, Wellman R, Feigelson HS et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: A retrospective cohort stud)/. J Natl Cancer Inst 2012; 104:1293-305.
  • Farolfi A, Melegari E, Aquilina M, et al. Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors. Heart. 2013;99(9):634-639. https://doi.org/10.1136/ heartjnl-2012-303151
  • Robert N, Leyland-Jones B, Asmar L et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006; 24:2186-92.
  • Burstein H, Kuter I, Campos S et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001; 19:2122-30.
  • Advani PP, Ballman KV, Dockter TJ, Colon-Otero G, Perez EA. Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial. J Clin Oncol. 2016;34(6):581-581. https://doi.org/10.1200/ JCO.2015.61.8413
  • Romond EH, Jeong JH, Rastogi P, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012;30(31):3192-3199. https://doi.org/10.1200/JCO.2011.40.0010
  • Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2001;25(25):3808-3815. https://doi. org/10.1200/Jœ.2006.10.4916
  • Chow EJ, Baker KS, Lee SJ, et al. Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation. J Clin Oncol. 2014;32(3):191-198. https:// doi.org/10.1200/JCO.2013.52.6582
  • Armenian SH, Xu L, Ky B, et al. Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study. J Clin Oncol. 2016;34(10):1122-1130. https://doi.org/10.1200/JCO.2015.64.0409
  • Chavez-MacGregor M, Zhang N, Buchholz TA, et al. Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol. 2013;31(33):4222-4228. https://doi.org/10.1200/JCO.2013.48.1884
  • Mantarro S, Rossi M, Bonifazi M, et al. Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer. Intern Emerg Med. 2016;11(1):123-140. https://doi.org/10.1001/s11139-015-1362-x
  • Gunaldi M, Duman B, Afsar C et al. Risk factors for developing cardiotoxicity of trastuzumab in breast cancer patients: An observational single-centre study. J Oncol Pharm Pract 2016; 22:242-1.
  • Lemieux J, Diorio C, Cote M et al. Alcohol and HER2 polymorphisms as risk factor for cardiotoxicity in breast cancer treated with trastuzumab. Anticancer Res 2013; 33:2569-16.
  • Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol. 2010;1(10):564-515. https://doi. org/10.1038/nrcardio.2010.121
  • Pivot X, Suter T, Nabholtz JM, et al. Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study. Eur J Cancer. 2015;51(13):1660-1666. https://doi.org/10.1016/j.ejca.2015.05.028
  • Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;21(9):911-939. https://doi.org/10.1016/j.echo.2014.01.012
  • Lyon AR, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22(11):1945-1960. https://doi.org/10.1002/ejhf.1920
  • Виценя М. В., Агеев Ф. Т., Гилярое М. Ю., и соавт. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2,2020 (том 10).41, https://rosoncoweb.ru/standarts/RUSSCO/2020/2020-41.pdf
  • Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popovic ZB, Marwick TH. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol. 2013;61(1):77-84. https://doi.org/10.1016/jjacc.2012.09.035
  • Allen LA, Yood MU, Wagner EH, et al. Performance of claims-based algorithms for identifying heart failure and cardiomyopathy among patients diagnosed with breast cancer. Med Care. 2014;52(5):e30-e38. https://doi.org/10.1097/ MLR.0b013e31825a8c22
  • Sawaya H, Sebag IA, Plana JC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. 2012;5(5):596-603. https://doi.org/10.1161/CIRCIMAGING.112.973321
  • Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol. 2014:63(25 Pt A):2751-2768. https://doi. org/10.1016/j.jacc.2014.01.073
  • Negishi K, Negishi T, Haluska BA, Hare JL, Plana JC, Marwick TH. Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection. Eur Heart J Cardiovasc Imaging. 2014;15(3):324-331. https://doi.org/10.1093/ehjci/jet159
  • Baron T, Berglund L, Hedin EM, Flachskampf FA. Test-retest reliability of new and conventional echocardiographic parameters of left ventricular systolic function. Clin Res Cardiol. 2019;108(4):355-365. https://doi.org/10.1007/ s00392-018-1363-7
  • Celutkiené J, Pudil R, Lopez-Fernandez T, et al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC) [published correction appears in Eur J Heart Fail. 2021 Feb;23(2):345], Eur J Heart Fail. 2020;22(9):1504-1524. https://doi.org/10.1002/ejhf.1957
  • Touyz RM, Herrmann J. Cardiotoxicity with vascular endothelial growth factor inhibitor therapy. NPJ Precis Oncol. 2018;2:13. Published 2018 May 8. https:// doi.org/10.1038/s41698-018-0056-z
  • Curigliano G, Cardinale D, Dent S, et al. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J Clin. 2016;66(4):309-325. https://doi.org/10.3322/caac.21341
  • Pudil R, Mueller C, Celutkiené J, et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail. 2020;22(11):1966-1983. https://doi.org/10.1002/ejhf.2017
  • Cardinale D, Colombo A, Torrisi R, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010;28(25):3910-3916. https://doi.org/10.1200/Jœ.2009.27.3615
  • Ky B, Putt M, Sawaya H, et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab [published correction appears in J Am Coll Cardiol. 2016 Mar 22;67(11):1385]. J Am Coll Cardiol. 2014;63(8):809-816. https://doi.org/10.1016/jjacc.2013.10.061
  • Sawaya H, Sebag I A, Plana JC, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol. 2011;107(9):1375-1380. https://doi.org/10.1016j.amjcard.2011.01.006
  • Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891-975. https://doi.org/10.1002/ejhf.592
  • Christenson ES, James T, Agrawal V, Park BH. Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity. Clin Biochem. 2015;48(4-5):223-235. https://doi.org/10.1016H.clinbiochem.2014.10.013
  • Thavendiranathan P, Wintersperger BJ, Flamm SD, Marwick TH. Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy: a systematic review. Circ Cardiovasc Imaging. 2013;6(6):1080-1091. https://doi. org/10.1161/CIRCIMAGING.113.000899
  • Saunderson C.E.D, Plein S, Manisty CH. Role of cardiovascular magnetic resonance imaging in cardio-oncology, European Heart Journal -Cardiovascular Imaging, Volume 22, Issue 4, April 2021, Pages 383-396, https://doi.org/10.1093/ehjci/jeaa345
  • Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2017;35:893-911. https:// doi.org/10.1200/jc0.2016.70.5400
  • Gilchrist SC, Barac A, Ades PA, et al. Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors: A Scientific Statement From the American Heart Association. Circulation 2019;139(21):e997-e1012. https://doi.org/10.1161/ CIR.0000000000000679
  • Sturgeon KM, Ky B, Libonati JR, Schmitz KH. The effects of exercise on cardiovascular outcomes before, during, and after treatment for breast cancer. Breast Cancer Res Treat. 2014;143(2):219-226. https://doi. org/10.1007/s10549-013-2808-3
  • Kirkham AA, Davis MK. Exercise Prevention of Cardiovascular Disease in Breast Cancer Survivors. J Oncol. 2015;2015:917606. https://doi. org/10.1155/2015/917606
  • Scott JM, Nilsen TS, Gupta D, Jones LW. Exercise therapy and cardiovascular toxicity in cancer. Circulation. 2018;137:1176-1191. https://doi.org/ 10.1161/ CIRCULATIONAHA.117.024671
  • Scott JM, Zabor EC, Schwitzer E, et al. Efficacy of exercise therapy on cardiorespiratory fitness in patients with cancer: a systematic review and meta-analysis. J Clin Oncol. 2018;36:2297-2305. https://doi.org/10.1200/ JCO.2017.77.5809
  • Dittus KL, Lakoski SG, Savage PD, et al. Exercise-based oncology rehabilitation: leveraging the cardiac rehabilitation model. J CardiopulmRehabil Prev. 2015;35:130-139. https://doi.org/10.1097/HCR.0000000000000091
  • Schmid D, Leitzmann M F. Cardiorespiratory fitness as predictor of cancer mortality: a systematic review and meta-analysis. Ann Oncol 2015 Feb;26(2):272-8. https://doi.org/ 10.1093/annonc/mdu250.
  • Lipsetta A, Barretta S, Harunaa F, et al. The impact of exercise during adjuvant radiotherapy for breast cancer on fatigue and quality of life: A systematic review and meta-analysis. The Breast. Volume 32, April 2017, Pages 144-155.
  • Lahart IM, Metsios GS, NevillAM, CarmichaelAR. Physical activity forwomen with breast cancer after adjuvant therapy. Cochrane Database Syst Rev. 2018 Jan 29;1(1):CD011292. https://doi.org/0.1002/14651858.CD011292.pub2
  • Jones LW, Habel LA, Weltzien E et al. Exercise and risk of cardiovascular events in women with nonmetastatic breast cancer. J Clin Oncol 2016; 34:2743-9. https://doi.org/10.1200/JCO.2015.65.6603
  • Jones LW, Liu Q, Armstrong GTet al. Exercise and risk of major cardiovascular events in adult survivors of childhood Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2014; 32:3643-50.
  • Hayes SC, Spence RR, Galvao DA et al. Australian Association for Exercise and Sport Science position stand: optimising cancer outcomes through exercise. J Sci Med Sport 2009; 12:428-34.
  • Pacciarini MA, Barbieri B, Colombo T et al. Distribution and antitumor activity of adria-mycin given in a high-dose and a repeated low-dose schedule to mice. Cancer Treat Rep 1978; 62:791-800.
  • Valdivieso M, Burgess MA, Ewer MS et al. Increased therapeutic index of weekly doxorubicin in the therapy of non-small cell lung cancer: a prospective, randomized study. J Clin Oncol 1984;2:207-14.
  • Legha SS, Benjamin RS, Mackay B et al. Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous Infusion. Ann Intern Med 1982; 96:133-9.
  • Smith LA, Cornelius VR, Plummer CJ, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010;10:337. Published 2010 Jun 29. https://doi.org/10.1186/1471-2407-10-337
  • van Dalen EC, Michiels EM, Caron HN, Kremer LC. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev. 2010;2010(5):CD005006. Published 2010 May 12. https://doi. org/10.1002/14651858.CD005006.pub4
  • Rafiyath SM, Rasul M, Lee B, Wei G, Lamba G, Liu D. Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a metaanalysis. Exp Hematol Oncol. 2012;1(1):10. Published 2012 Apr 23. https:// doi.org/10.1186/2162-3619-1-10
  • U.S. Food and Drug Administration. Drug safety and availability. FDA statement on DOXIL (doxorubicin HCl liposome injection) for intravenous infusion. Available at: http: //www.ac--cessdata.fda.gov/drugsatfda_docs/ label/2012/ 050718s043lbl.pdf.
  • Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23 Suppl 7:vii155-vii166. https://doi.org/10.1093/ annonc/mds293
  • Slamon D, Eiermann W, Robert N et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC_T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC_TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her-2/neu-positive early breast cancer patients: BCIRG 006 Study. 32nd Annual San Antonio Breast Cancer Symposium 2009. Abstr. 62.
  • Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR Jr, et al. Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial. J Am Coll Cardiol. 2018;71(20):2281-2290. https://doi.org/10.1016/j. jacc.2018.02.049
  • Kaya MG, Ozkan M, Gunebakmaz O, et al. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. Int J Cardiol. 2013;167(5):2306-2310. https://doi.org/10.1016/j. jcard.2012.06.023
  • Guglin M, Krischer J, Tamura R, et al. Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer. J Am Coll Cardiol. 2019;73(22):2859-2868. https://doi. org/10.1016j.jacc.2019.03.495
  • Pituskin E, Mackey JR, Koshman S, et al. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity. J Clin Oncol. 2017;35(8):870-877. https://doi.org/10.1200/ JCO.2016.68.7830
  • Gulati G, Heck SL, Ree AH et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2\2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 2016; 37:1671-80
  • Heck SL, Mecinaj A, Ree AH, et al. Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA) Extended Follow-Up of a 2x2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol. Circulation. 2021 May 16. https://doi. org/10.1161/CIRCULATIONAHA. 121.054698 Epub ahead of print. PMID: 33993702.
  • Boekhout AH, Gietema JA, Milojkovic Kerklaan B, et al. Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2016;2(8):1030-1037. https://doi.org/10.1001/ jamaoncol.2016.1726
  • Georgakopoulos P, Roussou P, Matsakas E, et al. Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up. Am J Hematol. 2010;85(11):894-896. https://doi.org/10.1002/ ajh.21840
  • Bosch X, Rovira M, Sitges M, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol. 2013;61(23):2355-2362. https://doi.org/10.1016/jjacc.2013.02.072
  • SeiceanS, SeiceanA,Alan N, Plana JC, BuddGT, Marwick Th. Cardioprotective effect of ß-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure. Circ Heart Fail. 2013;6(3):420-426. https://doi.org/10.1161/CIRCHEARTFAILURE.112.000055
  • Akpek M, Ozdogru I, Sahin O, et al. Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail. 2015;17(1):81-89. https://doi.org/10.1002/ejhf.196
  • Seicean S, Seicean A, Plana JC, Budd GT, Marwick TH. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J Am Coll Cardiol. 2012;60(23):2384-2390. https://doi.org/10.1016/jjacc.2012.07.067
  • Abdel-Qadir H, Bobrowski D, Zhou L, et al. Statin Exposure and Risk of Heart Failure After Anthracycline- or Trastuzumab-Based Chemotherapy for Early Breast Cancer: A Propensity ScoreBMatched Cohort Study. J Am Heart Assoc. 2021;10(2):e018393. https://doi.org/10.1161/JAHA.119.018393
  • Acar Z, Kale A, Turgut M, et al. Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2011;58(9):988-989. https://doi.org/10.1016/jjacc.2011.05.025
  • Strumia E, Pelliccia F, DAmbrosio G. Creatine phosphate: pharmacological and clinical perspectives. Adv Ther. 2012;29(2):99-123. https://doi.org/10.1001/s12325-011-0091-4.
  • Wang W., Feng Z, Bai1 J. Cardioprotective effects of creatine phosphate sodium in elderly breast cancer patients under epirubicin adjuvant chemotherapy. Int J Clin Exp Med 2019;12(10):12418-12425 www.ijcem.com /ISSN:1940-5901/IJCEM0094064
  • U.S. Food and Drug Administration. Drug Safety and Availability. FDA statement on dexrazo-xane. Jul 20, 2011. Available at: http: //www.fda. gov/ Drugs/DrugSafety/ucm 263129.htm
  • Lyu YL, Kerrigan JE, Lin CP, et al. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res. 2001;61(18):8839-8846. https://doi. org/10.1158/0008-5412.CAN-01-1649
  • Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol. 2014;64(9):938-945. https:// doi.org/10.1016/j.jacc.2014.06.1161
  • Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol. 1991;15(4):1318-1332. https://doi.org/10.1200/Jœ.1991.15.4.1318
  • Marty M, Espie M, Llombart A, et al. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/ metastatic breast cancer patients treated with anthracycline-based chemotherapy. Ann Oncol. 2006;11(4):614-22.https://doi.org/10.1093/ annonc/mdj134
  • van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2011;2011(6):CD003911. Published 2011 Jun 15. https:// doi.org/10.1002/14651858.CD003911.pub4
  • Lipshultz SE, Scully RE, Lipsitz SR, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 2010;11(10):950-961. https://doi.org/10.1016/ S1410-2045(10)10204-1
  • Hensley ML, Hagerty KL, Kewalramani T, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol. 2009;21(1):121-145. https://doi. org/10.1200/Jœ.2008.11.2621
  • European Medicines Agency. Questions and answers on the review of dexrazoxane-contai-ning medicines, powder for solution for infusion, 500 mg. Outcome of a procedure underArticle 31 of Directive 2001/83/EC as amended.http: // www.ema.europa.eu/docs/en_GB/docu-ment_library/ Referrals document/Dexrazoxane_31/WC500108011.pdf.
  • Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114(23):2414-2481. https:// doi.org/10.1161/CIRCULATIONAHA.106.635144
  • Cardinale D, Ciceri F, Latini R, et al. Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial. Eur J Cancer. 2018;94:126-131. https://doi.org/10.1016/j.ejca.2018.02.005
  • Santoro C, Esposito R, Lembo M, et al. Strain-oriented strategy for guiding cardioprotection initiation of breast cancer patients experiencing cardiac dysfunction. Eur Heart J Cardiovasc Imaging. 2019;20(12):1345-1352. https:// doi.org/10.1093/ehjci/jez194
  • Thavendiranathan P, Negishi T, Somerset E et al. SUCCOUR Investigators. Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy. J Am Coll Cardiol. 2021 Feb 2;11(4):392-401. https://doi.org/10.1016/j. jacc.2020.11.020 Epub 2020 Nov 18. PMID: 33220426.
  • Pareek N, Cevallos J, Moliner P, et al. Activity and outcomes of a cardio-oncology service in the United Kingdom-a five-year experience. Eur J Heart Fail. 2018;20(12):1121-1131. https://doi.org/10.1002/ejhf.1292
  • Hamo CE, Bloom MW, Cardinale D, et al. Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 2: Prevention, Treatment, Guidelines, and Future Directions. Circ Heart Fail. 2016;9(2):e002843. https://doi.org/10.1161/ CIRCHEARTFAILURE.115.002843
  • Мареев В.Ю., Фомин И.В., Агеев Ф.Т. и соавт. Клинические рекомендации ОССН-РКО-РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология. 2018;58(6S):8-158[Mareev V.Yu., FominI.V., Ageev F.T., et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58(6S):8-158 (In Russ.)] https:// doi.org/10.18081/cardio.2415
  • Cardinale D, Colombo A, Lamantia G et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010 Jan 19;55(3):213-20. https://doi.org/10.1016/j. jacc.2009.03.095 PMID: 20117401
  • Gregorietti V, Rojo A, Coronel R et al. Use of sacubitril valsartan in heart failure due to postchemotherapy symptomatic ventricular dysfunction. Eur J Heart Fail 2018; 20 (Suppl/S1).Abstract: P2123.
  • Виценя М.В., Потехина А.В., Гаврюшина С.В., и соавт. Профилактика и лечение дисфункции левого желудочка и сердечной недостаточности, связанных с противоопухолевой терапией: возможности и перспективы. Эффективная фармакотерапия 2020; 16(8): 108-120. https://doi.org/10.33978/2307-3586-2020-16-18-108-120
  • Oliva S, Cioffi G, Frattini S, et al. Administration of angiotensin-converting enzyme inhibitors and p-blockers during adjuvant trastuzumab chemotherapy for nonmetastatic breast cancer: marker of risk or cardioprotection in the real world?. Oncologist. 2012;17(7):917-924. https://doi.org/10.1634/ theoncologist.2011-0445
  • Oliveira GH, Dupont M, Naftel D, et al. Increased need for right ventricular support in patients with chemotherapy-induced cardiomyopathy undergoing mechanical circulatory support: outcomes from the INTERMACS Registry (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol. 2014;63(3):240-248. https://doi.org/10.1016/jjacc.2013.09.040
  • Oliveira GH, Hardaway BW, Kucheryavaya AY, Stehlik J, Edwards LB, Taylor DO. Characteristics and survival of patients with chemotherapy-induced cardiomyopathy undergoing heart transplantation. J Heart Lung Transplant. 2012;31(8):805-810. https://doi.org/10.1016j.healun.2012.03.018
  • Rickard J, Kumbhani DJ, Baranowski B et al. Usefulness of cardiac resynchronization therapy in patients with adriamycin-induced cardiomyopathy. Am J Cardiol 2010; 105:522-6. https://doi.org/10.1016/j.amjcard.2009.10.024
  • Lenneman AJ, Wang L, Wigger M, et al. Heart transplant survival outcomes for adriamycin-dilated cardiomyopathy. Am J Cardiol. 2013;111(4):609-612. https://doi.org/10.1016H.amjcard.2012.10.048
  • Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol. 2002;13(5):699-709. https://doi. org/10.1093/annonc/mdf132
  • Nousiainen T, Jantunen E, Vanninen E, Hartikainen J. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer. 2002;86(11):1697-1700. https://doi.org/10.1038/ sj.bjc.6600346
  • Lyon A.R., Habibian M., Evertz R. et al. Diagnosis and treatment of left ventricular dysfunction and heart failure in cancer patients. e-Journal of Cardiology Practice 2019; Vol. 16, N° 40.
  • Ganatra S, Nohria A, Shah S, et al. Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series. Cardiooncology. 2019;5:1. Published 2019 Jan 29. https://doi.org/10.1186/s40959-019-0036-7
  • Lynce F, Barac A, Geng X, et al. Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. Breast Cancer Res Treat. 2019;175(3):595-603. https://doi.org/10.1007/s10549-019-05191-2
  • Leong DP, Cosman T, Alhussein MM, et al. Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity: A Phase I Trial. JACC CardioOncol. 2019;1(1):1-10. Published2019 Jul 17. https://doi.org/10.1016/jjaccao.2019.06.004
  • Chang HM, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1 [published correction appears in J Am Coll Cardiol. 2018 Feb 6;71(5):587]. J Am Coll Cardiol. 2017;70(20):2536-2551. https://doi. org/10.1016/j.jacc.2017.09.1096
  • Herrmann J, YangEH, IliescuCA, et al. VascularToxicities of Cancer Therapies: The Old and the New--An Evolving Avenue. Circulation. 2016;133(13):1272-1289. https://doi.org/10.1161/CIRCULATIONAHA.115.018347
  • Yusuf SW Daraban N, Abbasi N, Lei X, Durand JB, Daher IN. Treatment and outcomes of acute coronary syndrome in the cancer population. Clin Cardiol. 2012;35(7):443-450. https://doi.org/10.1002/clc.22007
  • Sara JD, Kaur J, Khodadadi R, et al. 5-fluorouracil and cardiotoxicity: a review. Ther Adv Med Oncol. 2018;10:1758835918780140. Published 2018 Jun 18. https://doi.org/10.1177/1758835918780140
  • Polk A, Vistisen K, Vaage-Nilsen M, Nielsen DL. A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity. BMC Pharmacol Toxicol. 2014;15:47. Published 2014 Sep 4. https://doi.org/10.1186/2050-6511-15-47
  • Bohdan M, Kowalczys A, Mickiewicz A, Gruchate M, Lewicka E. Cancer Therapy-Related Cardiovascular Complications in Clinical Practice: Current Perspectives. J Clin Med. 2021;10(8):1647. Published 2021 Apr 13. https:// doi.org/10.3390/jcm10081647
  • de Forni M, Bugat R, Sorbette F, Delay M, Bachaud JM, Chevreau C. Cardiotoxicité du 5-fluorouracile perfusion intraveineuse continue: étude clinique, prévention, physiopathologie. A propos d'une série de 13 cas [Cardiotoxicity of continuous intravenous infusion of 5-fluorouracil: clinical study, prevention and physiopathology. Apropos of 13 cases]. Bull Cancer. 1990;77(5):429-438.
  • Südhoff T, Enderle MD, Pahlke M, et al. 5-Fluorouracil induces arterial vasocontractions. Ann Oncol. 2004;15(4):661-664. https://doi.org/10.1093/ annonc/mdh150
  • Stewart T, Pavlakis N, Ward M. Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina. Intern Med J. 2010;40(4):303-307. https://doi.org/10.1111/j.1445-5994.2009.02144.x
  • Grunwald MR, Howie L, Diaz LA Jr. Takotsubo cardiomyopathy and Fluorouracil: case report and review of the literature. J Clin Oncol. 2012;30(2):e11-e14. https://d0i.org/10.1200/JC0.2011.38.5278
  • Smith SA, Auseon AJ. Chemotherapy-induced takotsubo cardiomyopathy. Heart Fail Clin. 2013;9(2):233-x. https://doi.org/10.1016/j. hfc.2012.12.009
  • Cerny J, Hassan A, Smith C, Piperdi B. Coronary vasospasm with myocardial stunning in a patient with colon cancer receiving adjuvant chemotherapy with FOLFOX regimen. Clin Colorectal Cancer. 2009;8(1):55-58. https://doi. org/10.3816/CCC.2009.n.009
  • Ambrosy AP, Kunz PL, Fisher GA, Witteles RM. Capecitabine-induced chest pain relieved by diltiazem. Am J Cardiol. 2012;110(11):1623-1626. https://doi. org/10.1016/j.amjcard.2012.07.026
  • Boyle JJ, Wilson B, Bicknell R, Harrower S, Weissberg PL, Fan TP. Expression of angiogenic factor thymidine phosphorylase and angiogenesis in human atherosclerosis. J Pathol. 2000;192(2):234-242. https://doi.org/10.1002/1096-9896(2000)9999:9999<::AID-PATH699-3.0.C0;2-9
  • Coward J, Maisey N, Cunningham D. The effects of capecitabine in Raynaud's disease: a case report. Ann Oncol. 2005;16(5):835-836. https:// doi.org/10.1093/annonc/mdi144
  • Jensen SA, Sßrensen JB. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol. 2006;58(4):487-493. https://doi.org/10.1007/s00280-005-0178-1
  • Rowinsky EK, McGuire WP, Guarnieri T, Fisherman JS, Christian MC, Donehower RC. Cardiac disturbances during the administration of taxol. J Clin Oncol. 1991;9(9):1704-1712. https://doi.org/10.1200/JC0.1991.9.9.1704
  • Schrader C, Keussen C, Bewig B, von Freier A, Lins M. Symptoms and signs of an acute myocardial ischemia caused by chemotherapy with Paclitaxel (Taxol) in a patient with metastatic ovarian carcinoma. Eur J Med Res. 2005;10(11):498-501.
  • Berliner S, Rahima M, Sidi Y, et al. Acute coronary events following cispl atin-based chemotherapy. Cancer Invest. 1990;8(6):583-586. https://doi. org/10.3109/07357909009018924
  • Jafri M, Protheroe A. Cisplatin-associated thrombosis. Anticancer Drugs. 2008;19(9):927-929. https://doi.org/10.1097/CAD.0b013e3283100e9c
  • Karabay KO, Yildiz O, Aytekin V. Multiple coronary thrombi with cisplatin. J Invasive Cardiol. 2014;26(2):E18-E20.
  • Togna GI, Togna AR, Franconi M, Caprino L. Cisplatin triggers platelet activation. Thromb Res. 2000;99(5):503-509. https://doi.org/10.1016/s0049-3848(00)00294-2
  • Dieckmann KP, Gerl A, Witt J, Hartmann JT; German Testicular Cancer Study Group. Myocardial infarction and other major vascular events during chemotherapy for testicular cancer. Ann Oncol. 2010;21(8):1607-1611. https:// doi.org/10.1093/annonc/mdp597
  • Ito D, Shiraishi J, Nakamura T, et al. Primary percutaneous coronary intervention and intravascular ultrasound imaging for coronary thrombosis after cisplatin-based chemotherapy. Heart Vessels. 2012;27(6):634-638. https://doi.org/10.1007/s00380-011-0222-5
  • Meinardi MT, Gietema JA, van der Graaf WT, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol. 2000;18(8):1725-1732. https://doi.org/10.1200/Jœ.2000.18.8.1725
  • Huddart RA, Norman A, Shahidi M, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol. 2003;21(8):1513-1523. https://doi.org/10.1200/JCO.2003.04.173
  • Haugnes HS, WethalT,Aass N, et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol. 2010;28(30):4649-4657. https://doi.org/10.1200/JCO.2010.29.9362
  • Feldman DR, Schaffer WL, Steingart RM. Late cardiovascular toxicity following chemotherapy for germ cell tumors. J Natl Compr Canc Netw. 2012;10(4):537-544. https://doi.org/10.6004/inccn.2012.0051
  • Gietema JA, Meinardi MT, Messerschmidt J, et al. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet. 2000;355(9209):1075-1076. https://doi.org/10.1016/s0140-6736(00)02044-4
  • Nuver J, Smit AJ, Sleijfer DT, et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer. 2004;40(5):701-706. https://doi. org/10.1016j.ejca.2003.12.012
  • Oh JH, Baum DD, Pham S, et al. Long-term complications of platinum-based chemotherapy in testicular cancer survivors. Med Oncol. 2007;24(2):175-181. https://doi.org/10.1007/BF02698037
  • Kachel DL, Martin WJ 2nd. Cyclophosphamide-induced lung toxicity: mechanism of endothelial cell injury. J Pharmacol Exp Ther. 1994;268(1):42-46.
  • Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med. 1981;141(6):758-763.
  • Katayama M, Imai Y, Hashimoto H, et al. Fulminant fatal cardiotoxicity following cyclophosphamide therapy. J Cardiol. 2009;54(2):330-334. https:// doi.org/10.1016/ljicc.2009.01.006
  • Stefenelli T, Kuzmits R, Ulrich W, Glogar D. Acute vascular toxicity after combination chemotherapy with cisplatin, vinblastine, and bleomycin for testicular cancer. Eur Heart J. 1988;9(5):552-556. https://doi.org/10.1093/ oxfordjournals.eurheartj.a062542
  • Soultati A, Mountzios G, Avgerinou C, et al. Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications. Cancer Treat Rev. 2012;38(5):473-483. https://doi.org/10.1016/j. ctrv.2011.09.002
  • Schwarzer S, Eber B, Greinix H, Lind P. Non-Q-wave myocardial infarction associated with bleomycin and etoposide chemotherapy. Eur Heart J. 1991;12(6):748-750.
  • Doll DC, List AF, Greco FA, Hainsworth JD, Hande KR, Johnson DH. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med. 1986;105(1):48-51. https://doi. org/10.7326/0003-4819-105-1-48
  • Samuels BL, Vogelzang NJ, Kennedy BJ. Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemotherapy. Cancer Chemother Pharmacol. 1987;19(3):253-256. https://doi.org/10.1007/BF00252982
  • Panella M, Ross JE, Garvin K, Martin A. Cardiac sudden death as a result of acute coronary artery thrombosis during chemotherapy for testicular carcinoma. J Forensic Sci. 2010;55(5):1384-1388. https://doi.org/10.1111/ j.1556-4029.2010.01437.x
  • Gallagher H, Carroll WM, Dowd M, Rochev Y. The effects of vinblastine on endothelial cells. Endothelium. 2008;15(1):9-15. https://doi. org/10.1080/10623320802092161
  • Schutz FAB, Je Y, Azzi GR, Nguyen PL, Choueiri TK. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol. 2011;22(6):1404-1412. https://doi. org/10.1093/annonc/mdq587
  • Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol. 2010;49(3):287-297. https://doi.org/10.3109/02841860903524396
  • Qi WX, Shen Z Tang LN, Yao Y. Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: an up-to-date meta-analysis. Crit Rev Oncol Hematol. 2014;92(2):71-82. https://doi. org/10.1016/j.critrevonc.2014.04.004
  • Kappers MH, van Esch JH, Sluiter W, Sleijfer S, Danser AH, van den Meiracker AH. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension. 2010;56(4):675-681. https://doi.org/10.1161/HYPERTENSIONAHA.109.149690
  • Winnik S, Lohmann C, Siciliani G, et al. Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis--implications for cardiovascular safety. Int J Cardiol. 2013;168(3):2453-2461. https://doi.org/10.1016/jJjcard.2013.03.010
  • Arima Y, Oshima S, Noda K, et al. Sorafenib-induced acute myocardial infarction due to coronary artery spasm. J Cardiol. 2009;54(3):512-515. https://doi.org/10.1016/jJjcc.2009.03.009
  • Porto I, Leo A, Miele L, Pompili M, Landolfi R, Crea F. A case of variant angina in a patient under chronic treatment with sorafenib. Nat Rev Clin Oncol. 2010;7(8):476-480. https://doi.org/10.1038/nrclinonc.2010.67
  • Naib T, Steingart RM, Chen CL. Sorafenib-associated multivessel coronary artery vasospasm. Herz. 2011;36(4):348-351. https://doi.org/10.1007/s00059-011-3444-5
  • Franco TH, Khan A, Joshi V, Thomas B. Takotsubo cardiomyopathy in two men receiving bevacizumab for metastatic cancer. Ther Clin Risk Manag. 2008;4(6):1367-1370. https://doi.org/10.2147/tcrm.s3960
  • Numico G, Sicuro M, Silvestris N, et al. Takotsubo syndrome in a patient treated with sunitinib for renal cancer. J Clin Oncol. 2012;30(24):e218-e220. https://d0i.org/10.1200/JC0.2012.42.4911
  • Sen F, Yildiz I, Basaran M, et al. Impaired coronary flow reserve in metastatic cancer patients treated with sunitinib. J BUON. 2013;18(3):775-781.
Еще
Статья научная